Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
This study has been completed.
Study NCT00006092 Information provided by National Cancer Institute (NCI)
First Received: August 3, 2000 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Chromosome Aberrations
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Interventions listed in this trial
arsenic trioxide
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Back to top of Main Content
